Sihuan Pharmaceutical Expands PLLA Filler Range With Six New NMPA-Approved Specifications

Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has issued an update.

Sihuan Pharmaceutical announced that its subsidiary Meiyan Space Biotechnology has received National Medical Products Administration approval in China for six new specifications of its polylactic acid (PLLA) facial filler, adding 60mg to 130mg formats to the existing 45mg, 75mg and 150mg portfolio. The broader dosage range is designed to more precisely match varying anti-aging needs from early to severe aging, enhance physicians’ operational flexibility by allowing finer adjustment of dilution and dosing, and strengthen Sihuan’s competitive edge in the fast‑growing regenerative medical aesthetics market by deepening its differentiated product matrix alongside PCL fillers and energy-based devices. Management positions the move as supporting an industry shift toward personalized, high-quality aesthetic treatments and expects to leverage its nationwide institutional coverage to accelerate commercialization, potentially driving the medical aesthetics segment into a new phase of scale growth.

The most recent analyst rating on (HK:0460) stock is a Sell with a HK$1.00 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group is a China-focused pharmaceutical company that has expanded into regenerative medical aesthetics, offering a portfolio of heavyweight Class III medical devices including PCL and PLLA dermal fillers, botulinum toxin, skin boosters and radiofrequency microneedling systems. Through its incubated subsidiary Meiyan Space Biotechnology, the Group is building a comprehensive, full-cycle medical aesthetics product matrix for the domestic market, supported by an extensive sales network covering more than 7,000 medical institutions.

Average Trading Volume: 25,616,767

Technical Sentiment Signal: Buy

Current Market Cap: HK$12.6B

For detailed information about 0460 stock, go to TipRanks’ Stock Analysis page.